8-K: Autonomix Medical Eyes $2.1 Million Capital Raise Through At-the-Market Offering

Autonomix Medical, Inc. announced an At Market Issuance Sales Agreement to potentially raise up to $2.1 million for working capital and general corporate purposes.

Summary

• Autonomix Medical, Inc. has entered into an At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc., allowing the company to sell shares of its common stock with an aggregate sales price of up to $2.1 million.
• The company intends to use the net proceeds from the sale of shares for working capital and general corporate purposes.
• Sales will be made under the company's shelf registration statement on Form S-3, which was filed on February 28, 2025.
• The agent will receive a commission of 3.0% of the gross proceeds from the sale of shares, and will be reimbursed for certain expenses.
• The company is not obligated to make any sales of shares under the agreement, and any determination to do so will depend on market conditions and the company's capital raising needs.
• The company retrospectively presented certain financial information and related disclosures included in the company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024, originally filed with the U.S. Securities and Exchange Commission (the SEC) on May 31, 2024.
• On October 24, 2024, the company effected a reverse stock split at a ratio of 1-for-20.
• As a result of the Reverse Stock Split, the number of shares of common stock outstanding was reduced from approximately 23.0 million shares to approximately 1.15 million shares, and the number of authorized shares of common stock remained at 500 million shares.
• On November 1, 2024, the company received notice from DTCC on behalf of the brokerage firms that hold the shares of Company common stock held in street name that in connection with the foregoing rounding of shares the Company would need to issue 271,846 shares of common stock.
• The company does not believe the number of shares being requested is correct based on the historical number of shareholders of its common stock and is aware of similar occurrences in recent months for other companies completing a reverse stock split.

Sentiment

Score: 6

Explanation: The announcement is neutral. While it involves a potential capital raise, it also highlights a dispute regarding share issuance, creating uncertainty.

Positives

• The at-the-market offering provides Autonomix Medical with a flexible way to raise capital.
• The company retains control over the timing and amount of shares sold.
• The reverse stock split was intended to increase the per share trading price of the Common Stock and make the Common Stock more attractive to a broader range of investors.

Negatives

• The company is disputing a request to issue 271,846 shares related to fractional shares from the reverse stock split, which may lead to potential liability.
• The company is not obligated to make any sales of shares under the agreement, and any determination to do so will depend on market conditions and the company's capital raising needs.

Risks

• Market conditions may prevent the company from raising the full $2.1 million.
• The company may face potential liability for its failure to issue the shares of common stock if it is determined that it is required to issue such shares.
• The company's inquiry into the calculations set forth in the request may be time consuming and costly.

Future Outlook

The company intends to use the net proceeds from the sale of the Shares for working capital and for general corporate purposes. The Company may face potential liability for its failure to issue the shares of common stock if it is determined that it is required to issue such shares.

Industry Context

At-the-market offerings are a common method for publicly traded companies, especially smaller ones, to raise capital incrementally without the need for a traditional underwritten offering. This approach provides flexibility and can be less dilutive than other financing methods if managed carefully.

Legal Proceedings

• The Company may face potential liability for its failure to issue the shares of common stock if it is determined that it is required to issue such shares.

Stakeholder Impact

• Shareholders may experience dilution if the company sells shares under the agreement.
• The company's ability to fund its operations and execute its business plan may be affected by its ability to raise capital.

Next Steps

• The company will file a shelf registration statement on Form S-3 with the SEC.
• The company will determine whether to sell shares under the agreement based on market conditions and capital needs.
• The company will continue its inquiry into the calculations set forth in the request regarding the issuance of 271,846 shares of common stock.

Key Dates